<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211846</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-202</org_study_id>
    <secondary_id>2014-000340-15</secondary_id>
    <nct_id>NCT02211846</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder</brief_title>
  <official_title>A Multicentre, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS Tablets in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics as well as the safety and&#xD;
      tolerability of mirabegron OCAS tablets after single-dose administration at different dose&#xD;
      levels in children and adolescents with NDO or OAB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2014</start_date>
  <completion_date type="Actual">September 21, 2015</completion_date>
  <primary_completion_date type="Actual">September 21, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: Cmax</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: tmax</measure>
    <time_frame>Day 1-7</time_frame>
    <description>The time after dosing when Cmax occurs (tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: AUCinf</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Area under the curve extrapolated until time is infinity (AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: t1/2</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Apparent terminal elimination half-life (t1/2 )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by adverse events, clinical laboratory evaluations, vital signs (including 24-h Holter for heart rate), electrocardiogram (ECG), physical examination, post-void residual volume (PVR)</measure>
    <time_frame>up to Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Neurogenic Detrusor Overactivity</condition>
  <condition>Overactive Bladder</condition>
  <condition>Pharmacokinetics of Mirabegron</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered under fed and fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>Mirabegron</arm_group_label>
    <other_name>Myrbetriq</other_name>
    <other_name>Betmiga</other_name>
    <other_name>Betanis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a documented diagnosis of:&#xD;
&#xD;
               -  Neurogenic detrusor overactivity (NDO), or&#xD;
&#xD;
               -  Idiopathic overactive bladder (OAB) according to International Children's&#xD;
                  Continence Society (ICCS) criteria.&#xD;
&#xD;
          -  Subject's weight/height:&#xD;
&#xD;
               -  Subject should have a body weight of ≥ 20.0 kg (all cohorts).&#xD;
&#xD;
               -  For NDO: subject is not suffering from malnutrition and is not severely&#xD;
                  overweight, in the opinion of the Investigator.&#xD;
&#xD;
               -  For OAB: subject's weight and height are within the normal percentiles (3rd to&#xD;
                  97th percentile) according to Centers for Disease Control and Prevention (CDC)&#xD;
                  growth charts.&#xD;
&#xD;
          -  Subject is able to swallow the study medication in accordance with the protocol.&#xD;
&#xD;
          -  Female subject must either:&#xD;
&#xD;
               -  Be of non-childbearing potential:&#xD;
&#xD;
               -  Clearly pre-menarchal or in the judgment of the Investigator is pre-menarchal&#xD;
&#xD;
               -  Documented surgically sterile.&#xD;
&#xD;
               -  Or, if of childbearing potential: Agree not to try to become pregnant during the&#xD;
                  study and for 28 days after the final study drug administration,&#xD;
&#xD;
               -  And have a negative urine pregnancy test pre-dose Day 1,&#xD;
&#xD;
               -  And, if heterosexually active agree to consistently use two forms of highly&#xD;
                  effective form of birth control starting at screening and throughout the study&#xD;
                  period and for 28 days after the final study drug administration.&#xD;
&#xD;
          -  Female subjects must agree not to breastfeed starting at screening and throughout the&#xD;
             study period, and for 28 days after the last study drug administration.&#xD;
&#xD;
          -  Female subject must not donate ova starting at screening and throughout the study&#xD;
             period, and for 28 days after the final study drug administration.&#xD;
&#xD;
          -  Male subject and their female spouse/partner who are of childbearing potential must be&#xD;
             using a highly effective form of contraception consisting of two forms of birth&#xD;
             control (one of which must be a barrier method) starting at screening and continuing&#xD;
             throughout the study period, and for 28 days after the final study drug&#xD;
             administration.&#xD;
&#xD;
          -  Male subject must not donate sperm starting at Screening and throughout the study&#xD;
             period, and for 90 days after study drug administration.&#xD;
&#xD;
          -  Subject and subject's parent(s)/legal guardian agree that the subject will not&#xD;
             participate in another interventional study while on treatment.&#xD;
&#xD;
          -  Subject and subject's parent(s)/legal guardian are willing and able to comply with the&#xD;
             study requirements and with the concomitant medication restrictions&#xD;
&#xD;
        Exclusion Criteria At Screening:&#xD;
&#xD;
          -  Subject is pregnant.&#xD;
&#xD;
          -  Subject has a known history of QTc prolongation or risk of QT prolongation (e.g.&#xD;
             hypokalemia, family history of Long QT Syndrome).&#xD;
&#xD;
          -  Subject has an abnormal (mean) pulse rate according to the ranges specified below: age&#xD;
             5 to less than 8 years: &lt; 60 bpm or &gt; 110 bpm; age 8 to less than 12 years: &lt; 55 bpm&#xD;
             or &gt; 100 bpm; age 12 to less than 18 years: &lt; 50 bpm or &gt; 100 bpm.&#xD;
&#xD;
          -  Subject has any clinically significant ECG abnormality.&#xD;
&#xD;
          -  Subject has mean systolic blood pressure greater than the 95th percentile according to&#xD;
             age and height and/or greater than 140 mmHg [National Institute of Health, 2005].&#xD;
&#xD;
          -  Subject has any clinically significant or unstable medical condition or disorder&#xD;
             which, in the opinion of the Investigator, precludes the subject from participating in&#xD;
             the study.&#xD;
&#xD;
          -  Subject has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater&#xD;
             than or equal to 2 times the upper limit of normal (ULN) or total bilirubin greater&#xD;
             than or equal to 1.5 times the ULN.&#xD;
&#xD;
          -  Subject has severe renal impairment (estimated glomerular filtration rate (MDRD) &lt; 30&#xD;
             mL/min).&#xD;
&#xD;
          -  Subject has any other clinically significant out of range results of urinalysis,&#xD;
             biochemistry or hematology.&#xD;
&#xD;
          -  Subject has a history or current diagnosis of any malignancy.&#xD;
&#xD;
          -  Subject has known or suspected hypersensitivity to mirabegron, other ß3-agonists, any&#xD;
             of the excipients used in the OCAS tablet formulation or previous severe&#xD;
             hypersensitivity to any drug.&#xD;
&#xD;
          -  Subject meets any of the contra-indications or precautions for use of mirabegron as&#xD;
             mentioned in the Investigator's Brochure (IB).&#xD;
&#xD;
          -  Subject has used mirabegron in the past (last intake less than 12 days before planned&#xD;
             reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject requires ongoing treatment with any of the following prohibited medications:&#xD;
&#xD;
               -  Any anticholinergic/antimuscarinic drugs within 5 half-lives prior to planned&#xD;
                  reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any drugs that are sensitive CYP2D6 substrates with a narrow therapeutic index&#xD;
                  (such as thioridazine, flecainide, propafenone, imipramine, desipramine) and&#xD;
                  sensitive P-gp substrates (such as digoxin, dabigatran) within 5 half-lives prior&#xD;
                  to the planned reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any moderate or strong cytochrome CYP3A4/5 or P-gp inhibitors or inducers&#xD;
                  including natural and herbal remedies (such as itraconazole, rifampicin,&#xD;
                  phenytoin, carbamazepine, St. John's Wort, grapefruit, Seville orange) within 5&#xD;
                  half-lives prior to the planned reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject has a positive urinary drug screen test for drugs of abuse.&#xD;
&#xD;
          -  Subject donated blood or blood products within 3 months prior to planned Day 1.&#xD;
&#xD;
          -  Subject has participated in another clinical trial and/or has taken an investigational&#xD;
             drug within 30 days (or 5 half-lives of the investigational drug, whichever is longer)&#xD;
             prior to the planned reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject's parent(s)/legal guardian is an employee of the Astellas Group, any Contract&#xD;
             Research Organization (CRO) involved, or the Investigator site executing the study.&#xD;
&#xD;
          -  Subject has current, untreated constipation (or fecal impaction for NDO patients). If&#xD;
             the constipation is being consistently treated for the last month, the subject can be&#xD;
             included.&#xD;
&#xD;
          -  Subject has been administered intradetrusor botulinum toxin injections; except if&#xD;
             given &gt; 4 months prior to screening and symptoms reappeared comparable to those before&#xD;
             botulinum toxin injections.&#xD;
&#xD;
        Exclusion Criteria At day 1:&#xD;
&#xD;
          -  Subject has a positive urinary drug screen test for drugs of abuse.&#xD;
&#xD;
          -  Subject has a positive alcohol breath test.&#xD;
&#xD;
          -  Subject has used mirabegron in the past (last intake less than 24 days before planned&#xD;
             reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject requires ongoing treatment with any of the following prohibited medications:&#xD;
&#xD;
               -  Any anticholinergics/antimuscarinics within 5 half-lives prior to intake of the&#xD;
                  reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any drugs that are sensitive CYP2D6 substrates with a narrow therapeutic index&#xD;
                  (such as thioridazine, flecainide, propafenone, imipramine, desipramine) and&#xD;
                  sensitive P-gp substrates (such as digoxin, dabigatran) within 5 half-lives prior&#xD;
                  to the reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any moderate or strong cytochrome CYP3A4/5 or P-gp inhibitors or inducers&#xD;
                  including natural and herbal remedies (such as itraconazole, rifampicin,&#xD;
                  phenytoin, carbamazepine, St. John's Wort) within 5 half-lives prior to reference&#xD;
                  day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject donated blood or blood products within 3 months prior to Day 1.&#xD;
&#xD;
          -  Subject (female subjects of childbearing potential) has a positive urinary pregnancy&#xD;
             test.&#xD;
&#xD;
          -  Subject has a current symptomatic urinary tract infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Research Physician</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site BE32009 Univ.Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32003 Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32004 AZ Groeninge, Campus Vercruyss</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32011 U.Z. Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45003 Aalborg Sygehus Nord</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45001 Uni Hosp of Aarhus, Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45005 Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45004 Børnelægen i Køge</name>
      <address>
        <city>Koege</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45002 Kolding Sygehus</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NO47001 Haukeland Sykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48003 Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001 Pomnik-Centrum Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38010 Mother and Child Health Care</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/patientStudySearch.aspx?RID=;;;178-CL-202</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Neurogenic detrusor overactivity (NDO)</keyword>
  <keyword>Overactive bladder (OAB)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

